Interpretation of interleukin-2 receptor alpha positive cells during induction chemotherapy for adult acute myelogenous leukaemia patients.
To correlate clinical outcomes with the expression of interleukin-2 receptor alpha (CD25) positive cells during induction chemotherapy (IC) in adult patients with acute myeloid leukaemia (AML), we investigated the prognostic importance of subsets of peripheral blood (PB) CD45+CD25+ cells. Seventy-five patients with newly diagnosed AML received the same initial IC; and serial PB samples were taken. The gated CD45/CD25 cell populations were used to compare the intensity of immunophenotypic signals based on the treatment timeline. Patients who responded poorly to IC demonstrated exceptionally higher levels of PB CD45+CD25+ cells by percentage (p = 0.003) or by absolute count (p = 0.046) on the seventh day (D + 7) of initial IC. In addition, patients in complete remission (CR) (n = 61) demonstrated relatively lower levels of steady PB CD45+CD25+ after standard IC. These results suggest that the expression of CD25 can be used to predict the response to IC during an early period of treatment.
Min
Woo-Sung
WS
Division of Hematology, Department of Internal Medicine, Catholic Hemopoietic Stem Cell Transplantation Center, Catholic University of Korea College of Medicine, Seoul, Korea.
Kim
Hee-Je
HJ
Choi
Young
Y
Jeong
Hye-Young
HY
Kim
Chun-Choo
CC
D000293:Adolescent; D000328:Adult; D005260:Female; D006801:Humans; D053645:Interleukin-2 Receptor alpha Subunit / Q000032:analysis*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000276:immunology*; D017493:Leukocyte Common Antigens / Q000032:analysis; D008297:Male; D008875:Middle Aged; D011379:Prognosis
C508017:IL2RA protein, human; D053645:Interleukin-2 Receptor alpha Subunit; D017493:Leukocyte Common Antigens; C516769:PTPRC protein, human